Figure 1 : Flow chart

Analyzed (n=58)

Excluded from analysis (n=0)

Sampled for biology (n=48)

Allocated to TA 1g : standard dose (n= 58)

Received allocated treatment (n=58)

Assessed for elligibility

Patient experiencing an hemorrhagic CS ≥ 800 mL

(n=175)

Excluded (n=0)

Randomized (n= 175)

## Allocation

Allocated to TA 0.5g: low dose (n= 57)

Received allocated treatment (n=57)

Allocated to placebo (n= 60)

Received placebo (n=60)

## Follow-Up

Lost of follow-up ( n= 0)

Protocol deviation (n=0)

Received additional dose (n= 7)

Lost of follow-up ( n= 0)

Protocol deviation (n=3) 1 patient with PPH <800 mL

1 patient received TA before inclusion

1 patient with previous thrombosis

Received additional dose (n= 5)

Lost of follow-up ( n= 0)

Protocol deviation (n=1)

1 patient with previous seizure

Received additional dose (n= 8)

## Analysis

Analyzed (n=57)

Excluded from analysis (n=0)

Sampled for biology (n=50)

Analyzed (n=60)

Excluded from analysis (n=0)

Sampled for biology (n=52)